Tiako Meyo et al. also studied the predictive value of PD-1, PD-L1, VEGFA, CD40 ligand, and CD44 for nivolumab therapy in advanced non-small cell lung cancer, which revealed a potential predictive role of baseline sCombo (sPD-1 and/or sPD-L1 expression) for nivolumab efficacy [42]. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.